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Prevalence of incidental breast cancer and
precursor lesions in autopsy studies: a
systematic review and meta-analysis
Elizabeth T. Thomas1, Chris Del Mar2, Paul Glasziou2, Gordon Wright1, Alexandra Barratt3 and Katy J. L. Bell2,3*
Abstract
Background: Autopsy studies demonstrate the prevalence pool of incidental breast cancer in the population, but
estimates are uncertain due to small numbers in any primary study. We aimed to conduct a systematic review of
autopsy studies to estimate the prevalence of incidental breast cancer and precursors.
Methods: Relevant articles were identified through searching PubMed and Embase from inception up to April
2016, and backward and forward citations. We included autopsy studies of women with no history of breast
pathology, which included systematic histological examination of at least one breast, and which allowed calculation
of the prevalence of incidental breast cancer or precursor lesions. Data were pooled using logistic regression
models with random intercepts (non-linear mixed models).
Results: We included 13 studies from 1948 to 2010, contributing 2363 autopsies with 99 cases of incidental cancer
or precursor lesions. More thorough histological examination (≥20 histological sections) was a strong predictor of
incidental in-situ cancer and atypical hyperplasia (OR = 126·8 and 21·3 respectively, p < 0·001), but not invasive cancer
(OR = 1·1, p = 0·75). The estimated mean prevalence of incidental cancer or precursor lesion was 19·5% (0·85%
invasive cancer + 8·9% in-situ cancer + 9·8% atypical hyperplasia).
Conclusion: Our systematic review in ten countries over six decades found that incidental detection of cancer in
situ and breast cancer precursors is common in women not known to have breast disease during life. The large
prevalence pool of undetected cancer in-situ and atypical hyperplasia in these autopsy studies suggests screening
programs should be cautious about introducing more sensitive tests that may increase detection of these lesions.
Keywords: Breast neoplasms, Mass screening, Early detection of cancer, Autopsy
Background
Breast cancer is common [1] and its incidence has been
rising [2], largely from increased early detection of can-
cer through breast screening [3]. For a woman deciding
whether or not to undergo mammography screening, the
potential benefits of screening include averting the devel-
opment of advanced breast cancer and possible premature
death from breast cancer. However, these benefits must be
considered alongside potential harms, one being the over-
diagnosis and overtreatment of screen-detected cancers
that would otherwise never become apparent during the
woman’s lifetime. Cancer overdiagnosis, the diagnosis of
cancers which never declare themselves during the
patient’s lifetime, may result from the detection of cancers
which are very slowly progressive, non-progressive or even
regressive, and may include overdiagnosis of both invasive
cancer and in-situ cancer [4–13]. Pre-cancer
overdiagnosis may also occur where there is detection of
lesions such as atypical hyperplasia which either do not
advance or do so only very slowly.
Autopsy studies may be used to estimate the size of the
prevalence pool of incidental cancer (and pre-cancerous
lesions) among people not known to have specific cancers
during life. The prevalence pool of incidental prostate can-
cer, for example, has been estimated as 5% at age < 30 years
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rising to 59% by age > 79 years [14]; and incidental thyroid
cancer as 5·7% overall, and 11·2% when the tissue is exam-
ined more intensively [15]. As such, autopsy studies can
provide an indication of the potential for overdiagnosis of
specific cancers if efforts to detect preclinical cancers and
pre-cancers are made. The prevalence pool of incidental
breast cancer was investigated in a systematic review of aut-
opsy studies in 1997, which reported a median rate of 1·3%
of undiagnosed invasive breast cancer and 8·9% of undiag-
nosed ductal carcinoma in-situ (DCIS) [16]. Potential breast
cancer overdiagnosis remains just as relevant now as then,
if not more so. Changes to screening programmes to in-
clude the screening of older women (>70 years of age), have
resulted in increased numbers of women undergoing
screening [17–21], and theoretically could increase overdi-
agnosis disproportionately [7, 22]. Moreover, increasingly
sensitive diagnostic screening technologies have meant
increased detection of a number of precursor lesions:
atypical ductal and atypical lobular hyperplasia (ADH and
ALH respectively) in addition to ductal, and lobular carcin-
oma in-situ (DCIS and LCIS respectively).
In this study we aimed to update the estimated size of
the prevalence pool (reservoir) of incidental breast cancer
and precursor lesions at autopsy, and identify factors that
were associated with increased prevalence of these lesions.
Methods
Protocol and registration
The review protocol was not registered.
Selection
We included autopsy studies of adult women (>age 18 years)
who had no history of pre-existing breast disease and which
included a systematic histological examination of at least one
breast. We excluded studies that did not report the women’s
age, or methodically examine the breast microscopically. The
principal outcomes were rates of incidental breast cancer
(invasive and in situ cancer), and precursor lesions (atypical
hyperplasia) diagnosed on histopathology.
Searching
We searched Medline and Embase using the terms listed
below, with no restrictions on year published, type of publi-
cation, or language (search terms created by a librarian). To
identify further papers for inclusion in the review we ran
forward citation searches and checked the references of all
papers identified by the search for inclusion in the review.
Finally, we repeated our original search to identify any add-
itional papers published during the period of data collection.
Search strategy (Medline)
1 exp. Breast Neoplasms/
2 exp. Breast/pa [Pathology]
3 Breast Diseases/pa [Pathology]
4 ((breast or mammary) adj3 (neoplasm* or neoplasia*
or tumour* or tumor* or cancer* or carcinoma* or
adenocarcinoma* or malignan* or pre-malignan* or
premalignan*)).tw.
5 or/1–4
6 Autopsy/
7 (autopsy* or autopsies or postmortem* or
post-mortem* or post mortem*).tw.
8 6 or 7
9 5 and 8
Validity assessment
We planned a priori sub-group analyses for the following
risk of bias study characteristics: consecutive versus non-
consecutive case selection, population based versus
hospital based studies, and the possibility that breast
cancer discovered at autopsy may have caused death. We
also planned subgroup analysis of the following pathology
validity characteristics: intensity of pathological examin-
ation (average number of sections submitted for histo-
pathology per case); whether the histopathology reporting
method used international standards (such as WHO [23]);
and peer review of the histopathology diagnosis.
Study selection and data abstraction
Two authors (KB and ET) independently checked the
titles and abstracts of all articles retrieved from Medline
and Embase searches, and the full text was obtained if
either author judged the article potentially relevant. The
same two authors then independently checked all the
full text articles for eligibility. Foreign language papers
were translated into English using Google Translate.
Disagreements were resolved through discussion with
two further authors (CDM and PG).
Two authors independently extracted data for English pa-
pers (KB and ET) and non-English papers (CDM and KB)
using standardized forms. We counted only one cancer or
precursor lesion diagnosis per woman – in the case where
more than one diagnosis was reported we chose the one of
the highest grade/stage (i.e. invasive carcinoma > in situ
carcinoma > atypical hyperplasia). We also only counted
lesions which were not diagnosed during life – where this
was uncertain, we were conservative and did not count the
lesion. Disagreements were decided through discussion. We
extracted data at the study level on: cancer and precursor
prevalence, age, year that autopsies were performed, and the
validity measures as described above. Where available, we
also extracted data at the within-study level for women
<70 years and ≥70 years on: cancer and precursor prevalence.
Quantitative data synthesis
Our main summary measures were the prevalence of previ-
ously undiagnosed breast cancer or precursors: invasive
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breast cancer, in-situ breast cancer (DCIS and LCIS), and
atypical hyperplasia (ADH and ALH). We pooled data
from all studies using logistic regression models with ran-
dom intercepts to represent the distribution of underlying
cancer/precursor prevalences between different popula-
tions. This type of model also allowed for the nested struc-
ture of the data for the within-study analysis of age-specific
prevalence estimates. We used the model to examine the
impact of the validity characteristics on the prevalence esti-
mates. SAS 9.4 was used for all analyses. The NLMIXED
procedure was used to build the models, as has been rec-
ommended [24].
Results
We identified 1925 abstracts from Medline and Embase
(search date 8th April 2016): 87 papers were retrieved for
full text review; 71 of which did not meet our selection cri-
teria (Fig. 1). Several of the remaining 16 studies used
overlapping data: for each set of potentially overlapping re-
ports, we chose the one that reported on the largest num-
ber of women, in the most detail (usually the most recent
report), which resulted in 10 studies included from the ori-
ginal search. A further 10 potential papers were identified
from the references and forward citation searches of the
10 included papers; of these 3 studies were included, with
one [25] contributing two datasets (studies performed in
two different countries). A total of 13 studies [25–37], con-
tributing 14 datasets were included in the study level ana-
lysis, Table 1. There were 2363 women and 99 cases.
There were separate data on cancer and precursor preva-
lence for women <70 years and ≥70 years in 6 studies [26,
27, 30, 32, 33, 35] for the within-study analysis.
The median prevalence of: invasive cancer; in-situ cancer
(DCIS and LCIS); atypical hyperplasia (ADH and ALH);
and any of these lesions; were 1·1% (range 0–7·1%; mean =
1·5%), 0·0% (range 0–18·7%; mean = 4·5%), 3·4% (range 0–
14·5%; mean = 4·8%) and 7·4% (0–27%; mean = 10·9%)
respectively, Table 1. The overall prevalence of incidental
breast cancer or precursor lesion for the studies by the me-
dian year the autopsies were done (or year-of-publication if
this information was unavailable) showed no visible trend
in estimated prevalence over time, from the earliest study
in 1947, to the most recent study in 2010, Fig. 2. We
formally tested for temporal trend in the models below.
Predictors for incidental prevalence of each category
(invasive cancer, in-situ cancer, atypical hyperplasia) and
all categories combined, are presented in Table 2. Their
prevalence differed between studies (test for random inter-
cepts p < 0·001 in each model). More thorough pathology
examination yielded greater prevalences of in-situ cancer,
atypical hyperplasia and all categories combined (OR =
126·8, 21·3 and 29·3, if ≥20 sections taken on average
compared to <20 sections taken on average respectively),
but not invasive cancer (OR = 1·1), Fig. 3. The prevalence
of each category, and of all categories combined was not
statistically higher for studies with an older average age of
participants. There was weak evidence for higher preva-
lence of in-situ cancer in studies that used consecutive
cases (p = 0.06), and of all categories combined for more
recent studies (p = 0.09), but this disappeared after adjust-
ing for thoroughness of pathology examination (p = 0.11
and p = 0.37 respectively). There was a higher prevalence of
invasive cancer, (but not in-situ cancer or atypical hyperpla-
sia), for the study (contributing two datasets) [25] reporting
breast cancer discovered at autopsy which may have con-
tributed to the women’s deaths. None of the other available
validity characteristics were statistically significant.
The mean prevalence of invasive cancer was 1·5%. After
excluding the study in which the breast cancer discovered
at autopsy may have contributed to death [25], it was
0·85%. The mean prevalence of in-situ cancer and atypical
hyperplasia, with modelled adjustment upwards for less
thorough studies, was 8·9% and 9·8% respectively. The over-
all mean cancer and precursor prevalence, with adjustment
of in situ and precursor estimates upwards for less
thorough studies, (no adjustment for invasive cancer), was
19·5% (0·85% + 8·9% + 9·8%).
When we repeated the analysis, limiting it to six studies
with separate data on women <70 years and ≥70 years,
there were insufficient data to perform a direct within-
study comparison while adjusting for thoroughness of
pathology examination.
Discussion
Our systematic review of 13 studies (14 datasets) in ten
countries over six decades of 2363 autopsies and 99 cases
of incidental cancer or neoplastic precursor lesions, found
that incidental breast cancer and its precursors are com-
mon in women not known to have breast disease during
life. The estimates from these autopsy studies represent the
best available evidence to answer the important question
on the size of the prevalence pool of incidental breast
cancer and precursor lesions.
The majority of incidental lesions appear to be precursors
for invasive cancer (cancer in-situ and atypical hyperpla-
sia). However the smaller prevalence pool of incidental in-
vasive cancers appeared easier to find, with even the least
thorough studies reporting cases. Unlike invasive cancer
which was unrelated to the number of sections submitted
for pathology examination, the estimated prevalence of can-
cer in-situ and atypical hyperplasia was strongly related to
the thoroughness of microscopic examination. The odds of
finding in-situ cancer and atypical hyperplasia were 127
times and 21 times higher respectively, in the studies where
at least 20 sections were examined compared to those
where less than 20 sections were examined. We could find
no other clear predictors, including age, although this may
be attributed to a paucity of data on women ≥70 years.
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Our study builds on the evidence from a previous sys-
tematic review of incidental cancer discovered at autopsy
[16]. We included six of the seven studies in that review
(we excluded one study [38] as those data were included
in a later report [33]). Our sensitive search strategy un-
covered a further six reports which were published at
the time of the previous review, but not discovered by
them. We also found one more recent study [25] which
contributed 2 datasets. Pooling these data enabled us to
report on the substantial prevalence pool of invasive
cancer, situ-cancer and precursor lesions (ADH and
ALH), and that the more thorough the microscopic
examination, the more these lesions are discovered.
Autopsy rates are now much lower than previous de-
cades; in addition, the widespread adoption of screening
in many countries means that contemporary studies risk
under-estimating the prevalence of incidental disease as
much of this may have already been detected (and treated)
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during life. Although the primary studies were conducted
over a long time period (from 1948 to 2010), all but one
were conducted in largely unscreened populations. The
most thorough studies were conducted in the 1970s and
1980s, and included both hospital and forensic studies.
Limitations to this review include variation in the preva-
lence of incidental breast cancer and precursors across the
studies, which could in part be due to underlying differ-
ences within the populations studied. Pathologists may
have differing thresholds for classifying lesions [39] and
differing levels of scrutiny with which they analyse lesions
- which, as already discussed, was the strongest predictor
of incidental breast cancer in-situ and atypical hyperplasia.
Our review was also limited by the absence of data on the
age-specific prevalence in most of the studies. We com-
pared older and younger women's prevalences of inciden-
tal cancer and precursors but had insufficient data to make
any conclusions on this. Insufficient information also pre-
vented us from being able to compare cancer prevalence
across race groups. In particular, there was a paucity of
data related to women of African descent (only one study).
The size of the prevalence pool of incidental invasive
breast cancer in unscreened populations may be used to
provide an approximate lower bound for the extent of
overdiagnosis associated with mammography screening:
true overdiagnosis rates are likely to be at least this large.
Our estimate of the prevalence of incidental invasive can-
cer, at 0·85%, is much less than the current life-time preva-
lence of invasive cancer for women in the USA of 12·4%
[40], or the life-time prevalence of screen-detected inva-
sive cancer of ~7·4% (assuming that about 60% of invasive
cancers diagnosed during life are detected by mammog-
raphy screening [41, 42]). If we assume that all of the
prevalence pool of incidental cancer would be detected
through screening (which is reasonable given the apparent
ease with which incidental invasive cancer was detected in
the autopsy studies), then the implications may be that at
least ~11% (~0·85/7·4%) of screen-detected invasive
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cancers, or at least ~7% (~0·85/12·4) of all invasive can-
cers, are overdiagnosed. Invasive cancers that would have
regressed if not detected by screening [43, 44] however,
will cause the lifetime prevalence of overdiagnosed can-
cers to be greater than the incidental cancer prevalence
discovered at autopsy in unscreened populations.
The excess lifetime prevalence of breast cancer in a
regularly screened population may be used to provide an
approximate upper bound for the extent of overdiagnosis
associated with mammography screening: true overdiag-
nosis rates are likely to be no larger than this. The lifetime
prevalence of invasive breast cancer in the USA in 1975–
1977 (prior to the introduction of screening) was 9.4% (1
in 10.6 women). Since 1987 after roll-out of nation-wide
mammography screening the life time prevalence has
been stable at around 12.5% (1 in 8 women). Some of the
increased risk in more recent times is because women are
now less likely to die of other causes and because of chan-
ging risk factor levels, but the main explanation appears to
be increased detection through mammography screening
[45]. The expected decline in lifetime prevalence as
screening rates stabilized has not eventuated [46] and a
large proportion of the excess 3% lifetime prevalence
(12.4% - 9.4%), which has now persisted for 30 years, is
likely to be due to overdiagnosis. The implications of this
are that up to ~40% (~3%/7.4%) of screen-detected inva-
sive cancers, or up to ~24% (~3/12.4%) of all invasive can-
cers, may be currently overdiagnosed. Others’ estimated
overdiagnosis rates fall between our approximate lower
and upper bounds [11, 43, 47–50].
For in-situ breast cancer, our estimate for the preva-
lence pool of incidental lesions is ~9%, much higher
than the current life-time prevalence of ~2·0% [40], and
lifetime prevalence of screen-detected in situ cancer of
1.6% (approximately 80–85% of in-situ cancers diag-
nosed during life are detected by screening [51]). This
means there is a much higher probability of screen de-
tected in-situ cancers being overdiagnosed (perhaps
most are overdiagnosed), again consistent with estimates
using other methods [11, 47].
The large pool of undetected cancer in-situ and atypical
hyperplasia in these autopsy studies suggest caution for
screening programs. First, as new breast screening tech-
nologies become more sensitive (e.g. digital mammography
and breast tomosynthesis), it is likely that the proportion of
overdiagnosed women will increase. Protocols for more in-
tense biopsy sampling of screen detected abnormalities, or
enhanced biopsy methods such as stereotactic vacuum-
assisted core biopsy, are also likely to further increase over-
diagnosis rates. Accordingly, new technologies and biopsy
protocols should evaluate whether any increased sensitivity
is for clinically important or overdiagnosed cancers, for
example by examining interval cancer rates in randomised
comparisons of alternative screening technologies [52].
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Fig. 3 Prevalence of incidental breast cancer or neoplastic precursor
lesion in studies by thoroughness of pathology examination. 3a:
Invasive cancer 3b: In-situ cancer 3c: Atypical Hyperplasia. Data
points are proportional to total number of women in each study
and are numbered according to year of study as follows: 1: Kiaer
[26], 2: Ryan [27]; 3: Sarnelli [28]; 4: Kramer [29]; 5: Nielsen 1984 [30];
6: Bartow [31]; 7: Nielsen 1987 [32]; 8: Alpers [33]; 9: Pisano [34]; 10:
Bhathal [35]; 11: Giarelli [36]; 12: Inai [37]; 13: Stalsberg (Ghana) [25];
14: Stalsberg (Norway) [25]
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Second, expansion of mammography screening programs
to include those aged ≥70 years may also increase the risk
of overdiagnosis and overtreatment [22]. The consequences
of overtreating older women may also be more serious than
for younger women because of their increased susceptibility
to adverse effects of treatment [53].
Conclusion
This review has confirmed that there is a large prevalence
pool of incidental breast cancer and precursor lesions
present across all ages. Policy-makers, researchers,
clinicians and women invited to undergo screening need to
be aware of the extent of overdiagnosis so breast cancer
detection can be improved and women do not undergo
treatment for an inconsequential finding detected through
breast cancer screening.
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